Thromboprophylaxis by Low Molecular Heparin During the Post-partum Period

Venous thromboembolism (VTE) became the 4th cause of maternal mortality and the 2nd direct cause of maternal mortality in France.

The re are only few randomized studies on the thromboprophylaxis during the post-partum period. This expose some discrepancy between French guidelines, French Society of Anesthesia & Intensive Care Medecine (SFAR) and National College of French Gynecologists and Obstetricians (CNGOF ).

The duration and adequate dose of low molecular heparin prescriptions are unclear.

The level of adequacy of thromboprophylaxis prescriptions at Centre Hospitalier Sud Francilien with the SFAR recommendations appears to be less than 50 % in a preliminary unpublished study.

Since this assessment, institutional protocol synthesizing thromboprophylaxis guidelines during the post-partum was exposed and validated among medical staff (both anaesthesiologists ang obstetricians).

Inclusion criteria

• >18 ages
• Who had given birth at Centre Hospitalier Sud Francilien
• Hospitalized during the puerperium at Centre Hospitalier Sud Francilien
• Being informed of the clinical trial and had offered any opposition for data collection

Exclusion criteria

• Curative treatment of thrombosis by Low molecular-weight or unfractioned heparin during pregnancy or post-partum period
• Curative anticoagulant therapy for any cause